Human Genome Sciences Initiates Second Randomized Phase 2 Trial Of HGS-ETR1 In Combination With Chemotherapy

Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that it has initiated dosing of patients in a Phase 2 clinical trial of HGS-ETR1 (mapatumumab) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. [click link for full article]

More: continued here

Filed under: Clinical Trials on December 24th, 2007